All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
NEW ORLEANS – The question of when a study is a failure is at times entirely in the eyes of the beholder. However, a study unveiled in the Crescent City suggests that echocardiography cannot distinguish which patients will benefit most from the Mitraclip device for secondary mitral valve regurgitation. At the same time, a secondary study that looked at quality-of-life issues provided a supportive context for the device vs. medical management – an increasingly important consideration as physicians, regulators and device makers move deeper into this era of personalized medicine.